Follow The Filings

CAI Caris Life Sciences

Caris Life Sciences earnings company data as of 4:45 AM ET 10/31

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 4 Nov EPS 0.03 — —
Rev $255.6M — —

Insider trades

Open-market buys and sales by CAI's executives, directors and 10% owners in the last 12 months, from their Form 4s

All CAI insider trades
  • $1.6M bought by 4 insiders
  • $12.4M sold by 2 insiders outside a trading plan
  • $1.7M sold by 1 insider under 10b5-1 plans
  1. John Russel Denton See Remarks
    Sale
    $239K 7,500 shares at $31.82 4.1% of stake
    Traded Sep 22 Filed Sep 23
  2. Brian J Brille See Remarks
    Sale
    $12.1M 400,000 shares at $30.33 64% of stake
    Traded Sep 17 Filed Sep 17
  3. Jon Halbert Director
    Buy
    $990K 68,000 shares at $14.56 +11% to stake
    Traded May 15 Filed Jul 13
  4. Jeff L Vacirca Director
    Buy
    $501K 31,050 shares at $16.15 +167% to stake
    Traded May 11 Filed May 12
  5. Luke Thomas Power See Remarks
    Planned sale
    $1.7M 62,250 shares at $26.58 39% of stake
    Traded Dec 11, 2025 Filed Dec 12, 2025
  6. David Baxley Spetzler President
    Buy
    $9,540 400 shares at $23.85 +0.1% to stake
    Traded Nov 7, 2025 Filed Nov 10, 2025
  7. John Russel Denton See Remarks
    Buy
    $101K 4,184 shares at $24.09 +84% to stake
    Traded Nov 7, 2025 Filed Nov 10, 2025

Also filed in the last 12 months, not counted as buying or selling: 21 stock grants, 6 option exercises, 5 share withholdings for taxes, 3 sales to cover taxes, and 2 gifts.

SEC filings

Recent issuer filings from EDGAR, 15 shown.

Filed Form Detail Links
8-K 7.01
SCHEDULE 13G/A —
SCHEDULE 13G/A —
8-K 2.02,9.01
10-Q
8-K 5.07
SCHEDULE 13G/A —
SCHEDULE 13G/A —
10-Q
8-K 2.02,9.01
DEF 14A
DEFA14A
SCHEDULE 13G/A —
8-K 1.01,1.02,2.03
10-K

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.